Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling-

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 2, 2011, Pages 156-167

  Leenders, Joost J ^a   Pinto, Yigal M ^a   Creemers, Esther E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac hypertrophy; Heart failure; Signaling; Therapeutic interventions; Transcriptional regulation

Indexed keywords

ADENYLATE KINASE; CALCINEURIN; CALSARCIN 1; CAVEOLIN 3; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 9; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 10; KRUPPEL LIKE FACTOR 15; KRUPPEL LIKE FACTOR 4; MAPK PHOSPHATASE 1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PKC INTERACTING COUSIN OF THIOREDOXIN; PROTEIN BACH1; PROTEIN CDC42; PROTEIN CHF1; PROTEIN LXRALPHA; PROTEIN NAB1; REPRESSOR PROTEIN; SIRTUIN 1; SIRTUIN 3; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; THIOREDOXIN 1; UNCLASSIFIED DRUG;

GENE TARGETING; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; GENE EXPRESSION REGULATION; HUMANS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS;

EID: 80955178910     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.04.017     Document Type: Review

References (145)

1. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215-262.
2. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
3. MacLellan W.R., Schneider M.D. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 2000, 62:289-319.
4. Hardt S.E., Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 2004, 63:500-509.
5. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
6. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
7. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
8. Latronico M.V., Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009, 6:419-429.
9. Small E.M., Frost R.J., Olson E.N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010, 121:1022-1032.
10. Rose B.A., Force T., Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010, 90:1507-1546.
11. Dickinson R.J., Keyse S.M. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 2006, 119:4607-4615.
12. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19:6341-6350.
13. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004, 110:718-723.
14. Yamaguchi O., Watanabe T., Nishida K., Kashiwase K., Higuchi Y., Takeda T., et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004, 114:937-943.
15. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A 2007, 104:14074-14079.
16. Liang Q., Bueno O.F., Wilkins B.J., Kuan C.Y., Xia Y., Molkentin J.D. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J 2003, 22:5079-5089.
17. Leenders J.J., Wijnen W.J., Hiller M., van der Made I., Lentink V., van Leeuwen R.E., et al. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem 2010, 285:27449-27456.
18. Zechner D., Thuerauf D.J., Hanford D.S., McDonough P.M., Glembotski C.C. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 1997, 139:115-127.
19. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000, 6:556-563.
20. Nemoto S., Sheng Z., Lin A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 1998, 18:3518-3526.
21. Watanabe K., Ma M., Hirabayashi K., Gurusamy N., Veeraveedu P.T., Prakash P., et al. Swimming stress in DN 14-3-3 mice triggers maladaptive cardiac remodeling: role of p38 MAPK. Am J Physiol 2007, 292:H1269-H1277.
22. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 2001, 98:12283-12288.
23. Zhang S., Weinheimer C., Courtois M., Kovacs A., Zhang C.E., Cheng A.M., et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 2003, 111:833-841.
24. Nishida K., Yamaguchi O., Hirotani S., Hikoso S., Higuchi Y., Watanabe T., et al. p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol 2004, 24:10611-10620.
25. Lezoualc'h F., Metrich M., Hmitou I., Duquesnes N., Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 2008, 44:623-632.
26. Maillet M., Lynch J.M., Sanna B., York A.J., Zheng Y., Molkentin J.D. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest 2009, 119:3079-3088.
27. Liu W., Zi M., Jin J., Prehar S., Oceandy D., Kimura T.E., et al. Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ Res 2009, 104:905-914.
28. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90:859-869.
29. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426.
30. Bueno O.F., De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001, 88:88-96.
31. Lim H.W., New L., Han J., Molkentin J.D. Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes. J Biol Chem 2001, 276:15913-15919.
32. Palm-Leis A., Singh U.S., Herbelin B.S., Olsovsky G.D., Baker K.M., Pan J. Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes. J Biol Chem 2004, 279:54905-54917.
33. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.S., Reddick R.L., et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 1997, 94:14730-14735.
34. Hayashi D., Kudoh S., Shiojima I., Zou Y., Harada K., Shimoyama M., et al. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun 2004, 322:310-319.
35. Frey N., Richardson J.A., Olson E.N. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci U S A 2000, 97:14632-14637.
36. Frey N., Barrientos T., Shelton J.M., Frank D., Rutten H., Gehring D., et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004, 10:1336-1343.
37. Frank D., Kuhn C., van Eickels M., Gehring D., Hanselmann C., Lippl S., et al. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Circulation 2007, 116:2587-2596.
38. Dorn G.W., Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005, 115:527-537.
39. Palaniyandi S.S., Sun L., Ferreira J.C., Mochly-Rosen D. Protein kinase C in heart failure: a therapeutic target?. Cardiovasc Res 2009, 82:229-239.
40. Samarel A.M. PICOT: a multidomain scaffolding inhibitor of hypertrophic signal transduction. Circ Res 2008, 102:625-627.
41. Jeong D., Cha H., Kim E., Kang M., Yang D.K., Kim J.M., et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res 2006, 99:307-314.
42. Cha H., Kim J.M., Oh J.G., Jeong M.H., Park C.S., Park J., et al. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol 2008, 45:796-803.
43. Jeong D., Kim J.M., Cha H., Oh J.G., Park J., Yun S.H., et al. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res 2008, 102:711-719.
44. Heineke J., Ruetten H., Willenbockel C., Gross S.C., Naguib M., Schaefer A., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A 2005, 102:1655-1660.
45. Kim Y., Phan D., van Rooij E., Wang D.Z., McAnally J., Qi X., et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 2008, 118:124-132.
46. Han J., Molkentin J.D. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc Med 2000, 10:19-22.
47. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000, 105:1395-1406.
48. van Rooij E., Doevendans P.A., de Theije C.C., Babiker F.A., Molkentin J.D., de Windt L.J. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 2002, 277:48617-48626.
49. Parlakian A., Charvet C., Escoubet B., Mericskay M., Molkentin J.D., Gary-Bobo G., et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 2005, 112:2930-2939.
50. Liang Q., De Windt L.J., Witt S.A., Kimball T.R., Markham B.E., Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001, 276:30245-30253.
51. Spiegelman B.M., Heinrich R. Biological control through regulated transcriptional coactivators. Cell 2004, 119:157-167.
52. Backs J., Olson E.N. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006, 98:15-24.
53. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
54. McKinsey T.A., Zhang C.L., Olson E.N. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 2001, 11:497-504.
55. Lu J., McKinsey T.A., Nicol R.L., Olson E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci U S A 2000, 97:4070-4075.
56. Sartorelli V., Huang J., Hamamori Y., Kedes L. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 1997, 17:1010-1026.
57. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
58. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008, 133:978-993.
59. Ago T., Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal 2007, 9:679-687.
60. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004, 24:8467-8476.
61. Song K., Backs J., McAnally J., Qi X., Gerard R.D., Richardson J.A., et al. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 2006, 125:453-466.
62. Dai Y.S., Xu J., Molkentin J.D. The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 2005, 25:9936-9948.
63. Bush E.W., McKinsey T.A. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets 2009, 13:767-784.
64. Xing W., Zhang T.C., Cao D., Wang Z., Antos C.L., Li S., et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 2006, 98:1089-1097.
65. van Rooij E., Fielitz J., Sutherland L.B., Thijssen V.L., Crijns H.J., Dimaio M.J., et al. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res 2010, 106:155-165.
66. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113:51-59.
67. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13:324-331.
68. Montgomery R.L., Davis C.A., Potthoff M.J., Haberland M., Fielitz J., Qi X., et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007, 21:1790-1802.
69. Montgomery R.L., Potthoff M.J., Haberland M., Qi X., Matsuzaki S., Humphries K.M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008, 118:3588-3597.
70. Nakagawa T., Guarente L. Sirtuins at a glance. J Cell Sci 2011, 124:833-838.
71. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
72. Bellizzi D., Rose G., Cavalcante P., Covello G., Dato S., De Rango F., et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 2005, 85:258-263.
73. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007, 100:1512-1521.
74. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 2009, 119:2758-2771.
75. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005, 115:500-508.
76. Sabri A., Hughie H.H., Lucchesi P.A. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003, 5:731-740.
77. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
78. Takano H., Zou Y., Hasegawa H., Akazawa H., Nagai T., Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 2003, 5:789-794.
79. Kobayashi-Miura M., Shioji K., Hoshino Y., Masutani H., Nakamura H., Yodoi J. Oxygen sensing and redox signaling: the role of thioredoxin in embryonic development and cardiac diseases. Am J Physiol 2007, 292:H2040-H2050.
80. Yamamoto M., Yang G., Hong C., Liu J., Holle E., Yu X., et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003, 112:1395-1406.
81. Pearson R., Fleetwood J., Eaton S., Crossley M., Bao S. Kruppel-like transcription factors: a functional family. Int J Biochem Cell Biol 2008, 40:1996-2001.
82. Uchida S., Tanaka Y., Ito H., Saitoh-Ohara F., Inazawa J., Yokoyama K.K., et al. Transcriptional regulation of the CLC-K1 promoter by myc-associated zinc finger protein and kidney-enriched Kruppel-like factor, a novel zinc finger repressor. Mol Cell Biol 2000, 20:7319-7331.
83. Fisch S., Gray S., Heymans S., Haldar S.M., Wang B., Pfister O., et al. Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2007, 104:7074-7079.
84. Haldar S.M., Lu Y., Jeyaraj D., Kawanami D., Cui Y., Eapen S.J., et al. Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Transl Med 2010, 2. 26ra.
85. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
86. Gray S., Feinberg M.W., Hull S., Kuo C.T., Watanabe M., Sen-Banerjee S., et al. The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem 2002, 277:34322-34328.
87. Liao X., Haldar S.M., Lu Y., Jeyaraj D., Paruchuri K., Nahori M., et al. Kruppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:334-338.
88. Yoshida T., Gan Q., Franke A.S., Ho R., Zhang J., Chen Y.E., et al. Smooth and cardiac muscle-selective knockout of Kruppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem 2010, 285:21175-21184.
89. Kee H.J., Kook H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 2009, 47:770-780.
90. Kee H.J., Eom G.H., Joung H., Shin S., Kim J.R., Cho Y.K., et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res 2008, 103:1259-1269.
91. Subramaniam M., Harris S.A., Oursler M.J., Rasmussen K., Riggs B.L., Spelsberg T.C. Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res 1995, 23:4907-4912.
92. Rajamannan N.M., Subramaniam M., Abraham T.P., Vasile V.C., Ackerman M.J., Monroe D.G., et al. TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: discovery and characterization of a novel signaling pathway. J Cell Biochem 2007, 100:315-325.
93. Hawse J.R., Subramaniam M., Ingle J.N., Oursler M.J., Rajamannan N.M., Spelsberg T.C. Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem 2008, 103:383-392.
94. Heaney A.P., Horwitz G.A., Wang Z., Singson R., Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 1999, 5:1317-1321.
95. Sachan N., Dey A., Rotter D., Grinsfelder D.B., Battiprolu P.K., Sikder D., et al. Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heart. Circ Res 2011, 108:437-445.
96. Geisler A., Jungmann A., Kurreck J., Poller W., Katus H.A., Vetter R., et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 2010, 18:199-209.
97. Suckau L., Fechner H., Chemaly E., Krohn S., Hadri L., Kockskamper J., et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009, 119:1241-1252.
98. Yang L., Jiang J., Drouin L.M., Agbandje-McKenna M., Chen C., Qiao C., et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 2009, 106:3946-3951.
99. Prasad K.M., Xu Y., Yang Z., Acton S.T., French B.A. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 2011, 18:43-52.
100. Swinnen M., Vanhoutte D., Van Almen G.C., Hamdani N., Schellings M.W., D'Hooge J., et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009, 120:1585-1597.
101. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
102. Bush E.W., McKinsey T.A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010, 106:272-284.
103. McKinsey T.A. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol 2010, http://dx.doi.org/10.1016/j.yjmcc.2010.11.009.
104. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
105. Berry J.M., Cao D.J., Rothermel B.A., Hill J.A. Histone deacetylase inhibition in the treatment of heart disease. Expert Opin Drug Saf 2008, 7:53-67.
106. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
107. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002, 105:1240-1246.
108. Haq S., Kilter H., Michael A., Tao J., O'Leary E., Sun X.M., et al. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med 2003, 9:944-951.
109. Zhou J., Lal H., Chen X., Shang X., Song J., Li Y., et al. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest 2010, 120:2280-2291.
110. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2002, 99:907-912.
111. Kerkela R., Kockeritz L., Macaulay K., Zhou J., Doble B.W., Beahm C., et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008, 118:3609-3618.
112. Jin H., Hadri L., Palomeque J., Morel C., Karakikes I., Kaprielian R., et al. KChIP2 attenuates cardiac hypertrophy through regulation of Ito and intracellular calcium signaling. J Mol Cell Cardiol 2010, 48:1169-1179.
113. Kuo H.C., Cheng C.F., Clark R.B., Lin J.J., Lin J.L., Hoshijima M., et al. A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell 2001, 107:801-813.
114. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 2010, 285:3133-3144.
115. Paulsson A.K., Franklin S., Mitchell-Jordan S.A., Ren S., Wang Y., Vondriska T.M. Post-translational regulation of calsarcin-1 during pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 48:1206-1214.
116. Rothermel B.A., McKinsey T.A., Vega R.B., Nicol R.L., Mammen P., Yang J., et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001, 98:3328-3333.
117. van Rooij E., Doevendans P.A., Crijns H.J., Heeneman S., Lips D.J., van Bilsen M., et al. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res 2004, 94:e18-e26.
118. Vega R.B., Rothermel B.A., Weinheimer C.J., Kovacs A., Naseem R.H., Bassel-Duby R., et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:669-674.
119. Cai J., Yi F.F., Yang L., Shen D.F., Yang Q., Li A., et al. Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension 2009, 53:539-548.
120. Park D.S., Woodman S.E., Schubert W., Cohen A.W., Frank P.G., Chandra M., et al. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 2002, 160:2207-2217.
121. Woodman S.E., Park D.S., Cohen A.W., Cheung M.W., Chandra M., Shirani J., et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002, 277:38988-38997.
122. Cook S.A., Novikov M.S., Ahn Y., Matsui T., Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 2003, 108:664-667.
123. Huang H., Tang Q.Z., Wang A.B., Chen M., Yan L., Liu C., et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-{beta}-activated kinase 1-dependent signaling. Hypertension 2010, 56:232-239.
124. Nunn C., Zou M.X., Sobiesiak A.J., Roy A.A., Kirshenbaum L.A., Chidiac P. RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal 2010, 22:1231-1239.
125. Rogers J.H., Tamirisa P., Kovacs A., Weinheimer C., Courtois M., Blumer K.J., et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest 1999, 104:567-576.
126. Tokudome T., Kishimoto I., Horio T., Arai Y., Schwenke D.O., Hino J., et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008, 117:2329-2339.
127. Yasukawa H., Hoshijima M., Gu Y., Nakamura T., Pradervand S., Hanada T., et al. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 2001, 108:1459-1467.
128. Tsoporis J.N., Marks A., Kahn H.J., Butany J.W., Liu P.P., O'Hanlon D., et al. S100beta inhibits alpha1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. J Biol Chem 1997, 272:31915-31921.
129. Tsoporis J.N., Marks A., Kahn H.J., Butany J.W., Liu P.P., O'Hanlon D., et al. Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice. J Clin Invest 1998, 102:1609-1616.
130. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
131. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.
132. Fiedler B., Lohmann S.M., Smolenski A., Linnemuller S., Pieske B., Schroder F., et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A 2002, 99:11363-11368.
133. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
134. Giampietri C., Petrungaro S., Musumeci M., Coluccia P., Antonangeli F., De Cesaris P., et al. c-Flip overexpression reduces cardiac hypertrophy in response to pressure overload. J Hypertens 2008, 26:1008-1016.
135. Gregoire S., Xiao L., Nie J., Zhang X., Xu M., Li J., et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 2007, 27:1280-1295.
136. Buitrago M., Lorenz K., Maass A.H., Oberdorf-Maass S., Keller U., Schmitteckert E.M., et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 2005, 11:837-844.
137. Wu S., Yin R., Ernest R., Li Y., Zhelyabovska O., Luo J., et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 2009, 84:119-126.
138. Fuller S.J., Davies E.L., Gillespie-Brown J., Sun H., Tonks N.K. Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochem J 1997, 323(Pt 2):313-319.
139. Kuhn C., Frank D., Will R., Jaschinski C., Frauen R., Katus H.A., et al. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem 2009, 284:17320-17327.
140. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010, 12:1220-1227.
141. De Keulenaer G.W., Wang Y., Feng Y., Muangman S., Yamamoto K., Thompson J.F., et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002, 90:690-696.
142. Mito S., Ozono R., Oshima T., Yano Y., Watari Y., Yamamoto Y., et al. Myocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme oxygenase-1. Hypertension 2008, 51:1570-1577.
143. Liu Y., Yu M., Wu L., Chin M.T. The bHLH transcription factor CHF1/Hey2 regulates susceptibility to apoptosis and heart failure after pressure overload. Am J Physiol 2010, 298:H2082-H2092.
144. Sakata Y., Kamei C.N., Nakagami H., Bronson R., Liao J.K., Chin M.T. Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A 2002, 99:16197-16202.
145. Yu M., Liu Y., Xiang F., Li Y., Cullen D., Liao R., et al. CHF1/Hey2 promotes physiological hypertrophy in response to pressure overload through selective repression and activation of specific transcriptional pathways. Omics 2009, 13:501-511.